ClinicalTrials.gov
public full text
Public Domain
Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
The ARTIST-CKD trial is a clinical study evaluating the effect of weekly subcutaneous administration of survodutide (3.6 mg) on kidney function in patients with chronic kidney disease (CKD) and elevated albuminuria. The primary objective is to determine whether survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria, regardless of diabetes status.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide#829843
- Effect of Glycosuria on Urinary Protein in Patients With Chronic Kidney Disease Treated With SGLT2 Inhibitors#869763
- Multi-disciplinary Participatory Design of a Process to Deliver a CKD Diagnosis in Primary Care#834224
- Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025)#300644
- Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease#800825
Record · ID 824999
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive